Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Aquaporin-4 water transport / glymphatic clearance: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| AQP4 | participates_in | gene | 0.46 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| SASP-Driven Aquaporin-4 Dysregulation | 0.782 | neurodegeneration | Senolytic therapy for age-related neurod |
| Aquaporin-4 Polarization Rescue | 0.732 | neurodegeneration | 4R-tau strain-specific spreading pattern |
| Glymphatic System-Enhanced Antibody Clearance Reversal | 0.537 | neurodegeneration | Blood-brain barrier transport mechanisms |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.732
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| Proposed experiment from debate on Perivascular spaces and glymphatic | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $240,000 |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Proposed experiment from debate on Perivascular spaces and glymphatic | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Vascular Contributions to Alzheimer Disease and Mixed Pathology | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Aquaporin-4 in glymphatic system, and its implication for central nervous system [PMID:36796590] | Peng S, Liu J, Liang C, Yang L, Wang G | Neurobiol Dis | 2023 | 2 |
| Uncommon inflammatory/immune-related myelopathies. [PMID:34715593] | Valencia-Sanchez C, Flanagan EP | J Neuroimmunol | 2021 | 2 |
| Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multi [PMID:40773034] | Leitner U, Chew SH, Blanch J, Viswanatha | J Neurol | 2025 | 1 |
| B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum [PMID:39222408] | Bennett JL, Pittock SJ, Paul F, Kim HJ, | Ann Clin Transl Neurol | 2024 | 1 |
| B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4. [PMID:38383779] | Afzali AM, Nirschl L, Sie C, Pfaller M, | Nature | 2024 | 1 |
| Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic str [PMID:34530847] | Carnero Contentti E, Correale J | J Neuroinflammation | 2021 | 1 |
| Glymphatic System Impairment in Alzheimer's Disease and Idiopathic Normal Pressu [PMID:31959516] | Reeves BC, Karimy JK, Kundishora AJ, Mes | Trends Mol Med | 2020 | 1 |
| Inebilizumab-cdon. [PMID:32936251] | Unknown | American journal of health-sys | 2020 | 1 |
| The glymphatic pathway in neurological disorders. [PMID:30353860] | Rasmussen MK, Mestre H, Nedergaard M | Lancet Neurol | 2018 | 1 |
| Sleep drives metabolite clearance from the adult brain. [PMID:24136970] | Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th | Science | 2013 | 1 |
| Ganglion Cell Layer Compared With Inner Plexiform Layer Atrophy After Optic Neur [PMID:41881459] | Filippatou AG, Gakis G, Bacchetti A, Kim | Neurology(R) neuroimmunology & | 2026 | 0 |
| β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708] | Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et | Acta Pharmacol Sin | 2026 | 0 |
| CCR2 knockdown attenuates post-hemorrhagic hydrocephalus and improves glymphatic [PMID:41539459] | Deng H, Zhang S, Wang H, Liu X, Zhong K | Exp Neurol | 2026 | 0 |
| NRF2 deficit prevents pathologic Tau seeding and spreading in an induced tauopat [PMID:41650822] | López-Sampere Y, Mengod Soler P, Roca-Pe | Redox Biol | 2026 | 0 |
| Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis opt [PMID:41665955] | Qi F, Lennon VA, Zhao S, Guo Y, Ding H e | J Clin Invest | 2026 | 0 |
| Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit [PMID:41782198] | Bennett JL, Bhattacharyya S, Zabeti A, L | Mult Scler | 2026 | 0 |
| NMOSD and MOGAD: Updates on diagnostic criteria. [PMID:41927386] | Marignier R, Leal Rato M | Rev Neurol (Paris) | 2026 | 0 |
| Therapeutic updates in NMOSD and MOGAD: From present practice to future promise. [PMID:41927387] | Elosua-Bayés I, Cobo-Calvo A | Rev Neurol (Paris) | 2026 | 0 |
| Multimodal MR Imaging Reveals the Mechanisms of Post-Cardiac-Arrest Brain edema: [PMID:41933462] | Tan Y, Ye H, Ge Q, Wang P, Liu Z et al. | J Magn Reson Imaging | 2026 | 0 |
| Recurrent aquaporin 4-immunoglobulin G-positive neuromyelitis optica spectrum di [PMID:41915816] | Jiang X, Chen J, Wen Y, Yuan L, Zhang J | The Journal of international m | 2026 | 0 |
Multi-agent debates referencing this entity